Exploring Novel Biomarkers for Emphysema Detection

ConditionsCopdEmphysema
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMaastricht University

About this trial

The goal of this clinical trial is to evaluate whether voice or capnometry, alone or in combination with other (non invasive) biomarkers can be used to detect emphysema on chest CT-scan in people with chronic obstructive pulmonary disease (COPD). The main question it aims to answer is:

• Can a machine-learning based algorithm be developed that can classify the extent of emphysema on chest CT scan from patients with COPD, based on voice and/or capnometry.

Participants will:

* perform different voice-related tasks * perform capnometry twice (before/after exercise) * perform a light exercise task between tasks ( 5-sit-to-stand test) * undergo one venipuncture

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults aged over 18 years

current respiratory smptoms (any dyspnea, cough or sputum)

spirometry confirmed diagnosis of a non-fully reversible airflow obstruction, defined as a post bronchodilator Forced Expiratory Volume at one second/Forced Vital Capacity (FEV1/FVC ratio) < 0.7 and/or emphysemateus abnormalities on CT imaging.

presence of risk factors or causes associated with COPD

Disqualifiers

acute exacerbation of COPD within 8 weeks of start of the study

comorbidities affecting speech or breathing coordination (neuromuscular disease, CVA< BMI > 40)

comorbidities affecting speech characteristics of dyspnea (severe heart failure, interstitial lung disease)

comorbidities affecting respiratory system including but not exclusive to asthma or cystic fibrosis

Trial population

The source population (primary dataset) consists of COPD patients in whom a chest CT was performed within 12 months before inclusion into the study.

Trial design

Design model

Case-only

Time perspective

Cross-sectional

Treatments tested in this trial

  • voice sampling

    Other intervention

    Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated

  • capnometry

    Other intervention

    Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated

Treatment groups

200 Participants
are divided into 1 treatment group
Group A: COPD and/or emphysema2 interventions

Trial outcomes

Primary outcomes

1

percentage of participants having moderate to severe emphysema on a chest CT (defined as > 25%)

A baseline chest CT scan from each participant will be analysed using a lung parenchyma analysis software with automated 3-D quantification of emphysema. Emphysema will be defined as low attenuation areas with a density below -950 Hounsfield units. Patients will be either classified as having low emphysema (less or equal to 25% of emphysema on chest CT scan) or moderate to high emphysema (more than 25% of emphysema on chest CT scan)

Time frame
baseline
2

number of (non-linguistic) inhalations per syllable from sustained vowel

Participants will perform a sustained vowel (saying 'a') at rest and after light exercise from which several measurements can be obtained: Syllables per breath group, speaking rate, articulation rate, mean frequency, mean intensity, pitch variability, mean center of gravity, inhalations, non-linguistic inhalations, ratio voice/silence intervals. Based on previous research (Merkus J, 2020) HNR, shimer, vowel duration en number of (non-linguistic) inhalations per syllable were putative vocal biomarkers in COPD. First key determinant therefore is the number of (non-linguistic) inhalations per syllable during sustained vowel of each participant. This will be used as input for machine learning classification models (e.g. using logistic regression, support vector machines, random forests and/or decision tree) to classify emphysema on CT scan (\>25% vs ≤ 25%)

Time frame
baseline
3

harmonics-to-noise-ratio from sustained vowel

Participants will perform a sustained vowel (saying 'a') at rest and after light exercise from which several measurements can be obtained: Syllables per breath group, speaking rate, articulation rate, mean frequency, mean intensity, pitch variability, mean center of gravity, inhalations, non-linguistic inhalations, ratio voice/silence intervals. Based on previous research (Merkus J, 2020) HNR, shimer, vowel duration en number of (non-linguistic) inhalations per syllable were putative vocal biomarkers in COPD. Second key determinant therefore is the harmonics-to-noise ratio during sustained vowel. This will be used as input for machine learning classification models (e.g. using logistic regression, support vector machines, random forests and/or decision tree) to classify emphysema on CT scan (\>25% vs ≤ 25%)

Time frame
baseline
4

vowel duration from sustained vowel

Participants will perform a sustained vowel (saying 'a') at rest and after light exercise from which several measurements can be obtained: Syllables per breath group, speaking rate, articulation rate, mean frequency, mean intensity, pitch variability, mean center of gravity, inhalations, non-linguistic inhalations, ratio voice/silence intervals. Based on previous research (Merkus J, 2020) HNR, shimer, vowel duration en number of (non-linguistic) inhalations per syllable were putative vocal biomarkers in COPD. Third key determinant therefore is the vowel duration (in seconds) during sustained vowel. This will be used as input for machine learning classification models (e.g. using logistic regression, support vector machines, random forests and/or decision tree) to classify emphysema on CT scan (\>25% vs ≤ 25%)

Time frame
baseline

Secondary outcomes

1

serum sRAGE

Serum soluble receptor for advanced glycation end-products (sRAGE) from peripheral blood will be determined in each participant. Serum sRAGE is considered a blood biomarker for emphysema (Klont 2022). Serum sRAGE levels (in ng/mL) from each participant will be used as input variable for machine learning classification models (e.g. using logistic regression, support vector machines, random forests and/or decision tree) to classify emphysema on CT scan (\>25% vs ≤ 25%)

Time frame
baseline
2

ratio of residual volume to total lung capacity (RV/TLC) on body plethysmography

Emphysema can be measured using body plethysmography. Several variables can be measured with body plethysmography: total lung capacity (TLC), inspiratory capacity (IC), functional residual capacity (FRC), residual volume (RV), ratio of IC/TLC, ratio FRC/TLC and ratio RV/TLC. The ratio of RV/TLC might be the most sensitive measure for airtrapping as the first sign of emphysema and is therefore chosen as the key outcome measure of body plethysmograpy. RV/TLC ratio (expressed as Z-score) from each participant will be used as input variable for machine learning classification models (e.g. using logistic regression, support vector machines, random forests and/or decision tree) to classify emphysema on CT scan (\>25% vs ≤ 25%)

Time frame
baseline
3

diffusion capacity of the lungs for carbon monoxide

Diffusion capacity of the lungs for carbon monoxide (DLCO) is a measure of the lungs ability to transfer gas from air to the blood stream and a decrease in DLCO is associated with the extent of emphysema in chest CT scans. DLCO (expressed a Z-score) in each participant will be measured and used as input variable for machine learning classification models (e.g. using logistic regression, support vector machines, random forests and/or decision tree) to classify emphysema on CT scan (\>25% vs ≤ 25%)

Time frame
baseline
4

forced expiratory volume in one second

Forced expiratory volume in one second (FEV1) is a measure of severity of the underlying COPD. postbronchodilator FEV1 (expressed a Z-score) in each participant will be measured via spirometry. according to ERS/ATS guidelines. FEV1 (Z-score) will be used as input variable for machine learning classification models (e.g. using logistic regression, support vector machines, random forests and/or decision tree) to classify emphysema on CT scan (\>25% vs ≤ 25%)

Time frame
baseline

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Maastricht University

Lead sponsor

Roche Pharma AG

Collaborator